香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 承董事會命 公司秘書 盧詩曼 香港，二零二五年九月八日 於本公告刊發日期，董事會成員包括郭令海先生擔任執行主席； Christian K. NOTHHAFT （羅敬仁）先生 擔任執行董事及行政總裁；郭令山先生擔任非執行董事；黃嘉純先生， 銀紫荊星章，太平紳士 、 Paul J. BROUGH 先生及吳麗莎女士擔任獨立非執行董事。 董事會會議日期 國浩集團有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，董事會會議將於 二零二五年九月十九日（星期五）舉行，以考慮及批准（其中包括）發佈本公司及其附 屬公司截至二零二五年六月三十日止年度之全年業績公告及建議宣派末期股息（如有）。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 狀態: 新提交 | | --- | | 截至月份: 2025年8月31日 | 致：香港交易及結算所有限公司 公司名稱: 國浩集團有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00053 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 329,051,373 | | 0 | | 329,051,373 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 329,051,373 | | 0 | | 329,051,373 | 第 2 頁 共 10 頁 v 1.1.1 | 1 ...

Core Viewpoint - Suihengyun A (000531.SZ) reported a significant increase in net profit for the first half of 2025, despite a decline in revenue [1] Financial Performance - The company achieved an operating revenue of 2.07 billion yuan, representing a year-on-year decrease of 6.55% [1] - The net profit attributable to shareholders reached 217 million yuan, marking a year-on-year increase of 135.99% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 203 million yuan, reflecting a year-on-year growth of 133.76% [1] - Basic earnings per share were reported at 0.2081 yuan [1]

国浩集团(00053)发布公告，该公司的附属公司国浩房地产有限公司(国浩房地产)截至2025年6月30日止 年度取得收益19.16亿新加坡元，同比增加5.31%;公司股东应占溢利1.07亿新加坡元，同比减少16.71%， 国浩房地产的董事会建议宣派首期及末期股息每股普通股7仙。 ...

智通财经APP讯，国浩集团(00053)发布公告，该公司的附属公司国浩房地产有限公司(国浩房地产)截至 2025年6月30日止年度取得收益19.16亿新加坡元，同比增加5.31%;公司股东应占溢利1.07亿新加坡元， 同比减少16.71%，国浩房地产的董事会建议宣派首期及末期股息每股普通股7仙。 ...

格隆汇8月29日丨国浩集团(00053.HK)发布公告，截至2025年6月30日止六个月，国浩房地产实现收益 19.16亿新加坡元，同比增加5.3%；毛利为3.66亿新加坡元，同比减少7.2%；公司拥有人应占溢利为1.07 亿新加坡元，同比减少16.7%。 ...

國浩房地產有限公司 國浩房地產集團截至二零二五年六月三十日止 年度之財務業績摘要 (附註：「本公司」及「仙」分別指「國浩房地產」及「新加坡仙」。) | | 截至 2025 年 | 截至 2024 年 | | --- | --- | --- | | | 6 月 30 日止年度 | 6 月 30 日止年度 | | | | (重列)* | | | 千新加坡元 | 千新加坡元 | | 收益 | 1,916,402 | 1,819,751 | | 銷售成本 | (1,550,563) | (1,425,464) | | 毛利 | 365,839 | 394,287 | | 除稅前溢利 | 172,560 | 171,842 | | 稅項開支 | (33,747) | (75,804) | | 年內溢利 | 138,813 | 96,038 | | 應佔溢利： | | | | 本公司股東 | 107,050 | 128,531 | | 非控制權益 | 31,763 | (32,493) | | 年內溢利 | 138,813 | 96,038 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 ...

Group 1: Yunnan Baiyao Acquisition - Yunnan Baiyao announced a cash acquisition of 100% equity in An Guo Shi Ju Yao Tang for 660 million yuan [1] - Yunnan Baiyao is a leading company in the traditional Chinese medicine industry, with projected revenue exceeding 40 billion yuan and net profit reaching 4.749 billion yuan in 2024 [1] - An Guo Shi Ju Yao Tang specializes in the production and sales of traditional Chinese medicine pieces and has a strong profitability record, with a production capacity of 25,000 tons for traditional Chinese medicine pieces and 1,500 tons for formula granules [1] Group 2: Brain-Computer Interface (BCI) Sector - The BCI sector has seen significant stock performance, with an average increase of 48.67% in 2023, and several stocks, including Innovation Medical, have doubled in value [4][10] - Innovation Medical's stock reached a new high, with a year-to-date increase of 235.05%, despite the company reporting continuous net losses over the past six years [3][4] - The BCI technology is recognized as a key area for development in China's 14th Five-Year Plan, with a projected market size in the medical field reaching between 40 billion to 145 billion USD by 2030-2040 [8] Group 3: Research and Development in BCI - A significant breakthrough in BCI research was achieved by scientists who decoded "inner speech" with a 74% accuracy rate, which could aid patients with severe speech impairments [7] - The research involved implanting microelectrodes in the brain's motor cortex of participants with severe paralysis, demonstrating the potential for advanced human-computer interaction [7] - The BCI market in China is expected to grow from 3.2 billion yuan in 2024 to over 5.5 billion yuan by 2027, indicating a robust growth trajectory [8] Group 4: Company Participation in BCI - Various companies are engaging in the BCI industry through technology development, equipment provision, and strategic partnerships, with Innovation Medical investing in BCI-related firms [10] - Notable companies in the BCI space include Qiangnao Technology and Sanbo Brain Science, which are developing non-invasive BCI technologies [9][10] - A total of 27 BCI-related stocks have attracted institutional attention this year, with North Land Pharmaceutical receiving the most inquiries [11]

国浩集团(00053)发布附属公司 THE RANK GROUP PLC 截至2025年6月30日止年度业绩，收益7.95亿英 镑，同比增长8.26%;净利润4460万英镑，同比增长265.57%。 ...

智通财经APP讯，国浩集团(00053)发布附属公司 THE RANK GROUP PLC 截至2025年6月30日止年度业 绩，收益7.95亿英镑，同比增长8.26%;净利润4460万英镑，同比增长265.57%。 ...